ArticleJournal of ovarian research2026
Circumventing IFN-γ induced resistance in ovarian cancer with a double-hit: NKG2A knockout of PRAME-TCR expressing NK cells.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe success of NK cell therapies against solid tumors remains limited, possibly due to tumor resistance mechanisms associated with the upregulation of inhibitory ligands. Previous studies have demonstrated that expanded NK cells can lyse ovarian cancer cells and produce IFN-γ. However, secretion of IFN-γ within the tumor microenvironment, leads to the upregulation of both classical HLA class I and the non-classical HLA-E on bystander tumor cells, thereby contributing to resistance against NK cell-mediated cytotoxicity. To overcome this IFN-γ induced resistance, we developed NKG2A-knockout NK: TCR cells targeting PRAME (NK: PRAME
methodsPrimary NK cells were isolated from PBMCs, stimulated with cytokines, and genetically modified using CRISPR-Cas9 to knockout the KLRC1 gene, which encodes NKG2A. After stimulation, the NK cells were further engineered to express the PRAME-specific TCR. NK: PRAME
resultsFirst we observed that NK: PRAME cells without a KLRC1 knockout were not effective to lyse IFN-γ treated ovarian cancer cells, irrespective of upregulated HLA class I expression. To overcome HLA-E mediated inhibition, the CRISPR-Cas9 induced KLRC1 knockout was successfully achieved without negatively impacting NK: TCR cell engineering, expansion and further alterations in phenotype. As a result, the NK: PRAME
conclusionsThis dual-targeting strategy offers a unique advantage by enabling the targeting of both HLA-positive and HLA-negative tumor cells, promoting a pro-inflammatory environment and enhancing the efficacy of TCR-based immunotherapy for ovarian cancer and other solid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.